Vis enkel innførsel

dc.contributor.authorGrønberg, Bjørn Henning
dc.contributor.authorHalvorsen, Tarje Onsøien
dc.contributor.authorFløtten, Øystein
dc.contributor.authorBrustugun, Odd Terje
dc.contributor.authorBrunsvig, Paal Fr.
dc.contributor.authorAasebø, Ulf
dc.contributor.authorBremnes, Roy M.
dc.contributor.authorTollåli, Terje
dc.contributor.authorHornslien, Kjersti
dc.contributor.authorAksnessæther, Bjørg Y.
dc.contributor.authorLiaaen, Erik Dyb
dc.contributor.authorSundstrøm, Stein Harald
dc.date.accessioned2017-11-18T10:48:42Z
dc.date.available2017-11-18T10:48:42Z
dc.date.issued2015-10-23
dc.description.abstract<br>BACKGROUND: <br> Concurrent chemotherapy and thoracic radiotherapy (TRT) is recommended for limited disease small cell lung cancer (LD SCLC). Twice daily TRT is well documented, but not universally implemented - probably mainly due to inconvenience and concerns about toxicity. A schedule of three-week hypofractionated TRT is a commonly used alternative. This is the first randomized trial comparing twice daily and hypofractionated TRT in LD SCLC. <br>MATERIAL AND METHODS: <br> Patients received four courses of cisplatin/etoposide (PE) and were randomized to TRT of 42 Gy in 15 fractions (once daily, OD) or 45 Gy in 30 fractions (twice daily, BID) between the second and third PE course. Good responders received prophylactic cranial irradiation of 30 Gy in 15 fractions. <br>RESULTS: <br> 157 patients were enrolled between May 2005 and January 2011 (OD: n = 84, BID: n = 73). Median age was 63 years, 52% were men, 84% had performance status 0-1, 72% had stage III disease and 11% non-malignant pleural effusion. The treatment arms were well balanced. The response rates were similar (OD: 92%, BID: 88%; p = 0.41), but more BID patients achieved a complete response (OD: 13%, BID: 33%; p = 0.003). There was no difference in one-year progression-free survival (PFS) (OD: 45%, BID: 49%; p = 0.61) or median PFS (OD: 10.2 months, BID: 11.4 months; p = 0.93). The median overall survival in the BID arm was 6.3 months longer (OD: 18.8 months, BID: 25.1 months; p = 0.61). There were no differences in grade 3-4 esophagitis (OD: 31%, BID: 33%, p = 0.80) or pneumonitis (OD: 2%, BID: 3%, p = 1.0). Patients on the BID arm reported slightly more dysphagia at the end of the TRT. <br>CONCLUSION: <br> There was no difference in severe toxicity between the two TRT schedules. The twice daily schedule resulted in significantly more complete responses and a numerically longer median overall survival, but no firm conclusions about efficacy could be drawn from this phase II trial.en_US
dc.descriptionPublished version available at <a href=http://dx.doi.org/10.3109/0284186X.2015.1092584> http://dx.doi.org/10.3109/0284186X.2015.1092584 </a>en_US
dc.identifier.citationGrønberg BH, Halvorsen T, Fløtten Ø, Brustugun OT, Brunsvig PF, Aasebø U, Bremnes RM, Tollåli T, Hornslien K, Aksnessæther BY, Liaaen Ed, Sundstrøm SH. Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer. Acta Oncologica. 2016;55(5):591-597en_US
dc.identifier.cristinIDFRIDAID 1310353
dc.identifier.doi10.3109/0284186X.2015.1092584
dc.identifier.issn0284-186X
dc.identifier.issn1651-226X
dc.identifier.urihttps://hdl.handle.net/10037/11755
dc.language.isoengen_US
dc.publisherTaylor & Francisen_US
dc.relation.journalActa Oncologica
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Medisinske fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en_US
dc.subjectVDP::Midical sciences: 700::Clinical medical sciences: 750::Oncology: 762en_US
dc.subjectRadioterapi / strålebehandling / Radiotherapyen_US
dc.titleRandomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung canceren_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel